Purpose: The purpose was to evaluate the effect of thermal ablation combined with activated functional killer (AFK) cells immunotherapy for patients with malignant tumors.
Materials and Methods: A cohort of 10 patients with malignancies received thermal ablation combined with AFK cells immunotherapy. Progression-free survival (PFS), overall survival, laboratory test, and postoperative complications were assessed.
Results: The success rate of the combination therapy was 100% and no severe complications occurred. Five patients maintained in PFS (50%) during the follow-up. The median PFS was 11 months (range 3.5–16.75 months). The hemoglobin (P = 0.023), hematocrit (P = 0.034), and lymphocyte ratio (P = 0.023); neutrophil-to-lymphocyte ratio (P = 0.038), neutrophil ratio (P = 0.016), albumin (P = 0.006), and alkaline phosphatase (P = 0.029); CA-125 (P = 0.033); and D-dimer (P = 0.011) changed significant after ablation. Whereas the white blood cell count (P = 0.003), neutrophil count (P = 0.024), lymphocyte count (P =0.003), monocyte ratio (P = 0.008), and eosinophil ratio (P = 0.005) changed significantly after combination therapy. The lymphocytes (P = 0.001) in the surviving patients increased more significantly after treatment. After the combination therapy, the percentage of CD3 + cells (P = 0.016) and CD3⁺ CD8⁺ cells (P = 0.002) increased, while CD3^-CD16⁺ CD56⁺ (P = 0.002) and CD4⁺/CD8⁺ (P = 0.016) decreased.
Conclusion: Combination of thermal ablation and AFK cells immunotherapy is a safe and effective method for patients with malignancy. And adoptive immunotherapy with AFK cells may be helpful to prevent recurrence after thermal ablation in patients with advanced cancer.


中文翻译：

---

热消融联合活化功能性杀伤细胞免疫治疗癌症：一项回顾性研究


目的：评价热消融联合活化功能杀伤（AFK）细胞免疫治疗恶性肿瘤患者的疗效。
材料和方法：一组 10 名恶性肿瘤患者接受了热消融联合 AFK 细胞免疫治疗。评估了无进展生存期 (PFS)、总生存期、实验室检查和术后并发症。
结果：联合治疗成功率为100%，无严重并发症发生。5 名患者在随访期间保持 PFS (50%)。中位 PFS 为 11 个月（范围 3.5-16.75 个月）。血红蛋白 ( P = 0.023)、血细胞比容 ( P = 0.034) 和淋巴细胞比率 ( P= 0.023); 中性粒细胞与淋巴细胞比率 ( P = 0.038)、中性粒细胞比率 ( P = 0.016)、白蛋白 ( P = 0.006) 和碱性磷酸酶 ( P = 0.029)；CA-125 ( P = 0.033); 和 D-二聚体（P = 0.011）在消融后发生显着变化。而白细胞计数（P = 0.003）、中性粒细胞计数（P = 0.024）、淋巴细胞计数（P = 0.003）、单核细胞比率（P = 0.008）和嗜酸性粒细胞比率（P = 0.005）在联合治疗后发生了显着变化。存活患者的淋巴细胞（P = 0.001）在治疗后增加更显着。联合治疗后，CD3 +细胞百分比（P =0.016）和CD3⁺ CD8 ⁺细胞 ( P = 0.002) 增加，而 CD3 ^- CD16 ⁺ CD56 ⁺ ( P = 0.002) 和 CD4 ⁺ /CD8 ⁺ ( P = 0.016) 减少。
结论：热消融联合AFK细胞免疫治疗对恶性肿瘤患者是一种安全有效的治疗方法。使用 AFK 细胞进行过继免疫治疗可能有助于预防晚期癌症患者热消融后的复发。